We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.34B
AUM Growth
+$471M
Cap. Flow
+$471M
Cap. Flow %
20.11%
Top 10 Hldgs %
49.6%
Holding
148
New
13
Increased
17
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$59.2M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$51.5M
3
SWTX
SpringWorks Therapeutics
SWTX
+$33.1M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$25.3M
5
KLRS
Kalaris Therapeutics
KLRS
+$22M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$92.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$87.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$28.5M
4
CYTK icon
Cytokinetics
CYTK
+$13.2M
5
BLU
BELLUS Health Inc.
BLU
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 77.68%
2 Consumer Discretionary 2.9%
3 Financials 0.65%
4 Consumer Staples 0.17%
5 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
26
Erasca
ERAS
$6.3B
$24.7M 1.06%
3,172,221
– –
VIGL
27
DELISTED
Vigil Neuroscience
VIGL
$20.8M 0.89%
2,285,574
+1,164,383
+104% +$8.54M
EQRX
28
DELISTED
EQRx, Inc. Common Stock
EQRX
$19.8M 0.85%
4,000,000
– –
DNLI icon
29
Denali Therapeutics
DNLI
$3.84B
$18.4M 0.79%
600,000
– –
SDGR icon
30
Schrodinger
SDGR
$1.15B
$17.5M 0.75%
700,000
– –
REPL icon
31
Replimune Group
REPL
$454M
$15.5M 0.66%
900,000
– –
NTLA icon
32
Intellia Therapeutics
NTLA
$1.54B
$15.4M 0.66%
275,000
– –
KURA icon
33
Kura Oncology
KURA
$818M
$15M 0.64%
1,100,000
+50,000
+5% +$771K
GBIO
34
DELISTED
Generation Bio
GBIO
$14.9M 0.64%
281,419
– –
MRSN
35
DELISTED
Mersana Therapeutics
MRSN
$14.9M 0.63%
88,000
– –
FHTX icon
36
Foghorn Therapeutics
FHTX
$287M
$14.8M 0.63%
1,720,720
– –
VERV
37
DELISTED
Verve Therapeutics
VERV
$13.7M 0.59%
400,000
– –
SGEN
38
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$13.7M 0.58%
+100,000
New +$16.3M
ISEE
39
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.5M 0.57%
+750,000
New +$9.84M
OMGA
40
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$12.3M 0.53%
2,273,530
– –
WVE icon
41
Wave Life Sciences
WVE
$1.12B
$10.8M 0.46%
3,000,000
– –
EVO icon
42
Evotec
EVO
$689M
$10.1M 0.43%
1,149,425
– –
SE icon
43
Sea Limited
SE
$67B
$9.67M 0.41%
172,500
+115,000
+200% +$8M
SYRS
44
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.43M 0.4%
1,463,829
+1,063,829
+266% +$8.64M
ISEE
45
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.97M 0.38%
+500,000
New +$6.56M
ALPN
46
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.59M 0.37%
1,193,030
+600,000
+101% +$4.95M
RPTX
47
DELISTED
Repare Therapeutics
RPTX
$8.49M 0.36%
700,000
– –
AGEN
48
Agenus
AGEN
$286M
$8.2M 0.35%
203,800
+50,950
+33% +$2.6M
RNAC icon
49
Cartesian Therapeutics
RNAC
$219M
$8.01M 0.34%
162,773
– –
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
$7.62M 0.33%
400,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2022 Portfolio in Review

As of Q3 2022, Artal Group held 148 positions worth $2.34B, up 25% from $1.87B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $471M of net new capital in Q3 2022, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was argenx, an estimated $92.6M trimmed.

  • Artal Group's largest Q3 2022 buy was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q3 2022, an estimated $51.5M increase.
  • Artal Group's biggest Q3 2022 reduction was argenx, cutting an estimated $92.6M.
  • Artal Group fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $87.5M.
  • Artal Group's ten largest holdings make up 50% of its $2.34B portfolio in Q3 2022.
  • Artal Group opened 13 new positions and closed 13 in Q3 2022.
  • Artal Group's portfolio value rose 25% quarter-over-quarter to $2.34B.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.